-
Affected by the new policy of CDE, the review of "heparin sodium injection", a heavy chemical drug of Changshan pharmaceutical industry, has fallen back
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA), the processing status of the heavy-duty drug "daparin sodium injection" declared by Changshan pharmaceutical industry has cha
-
Category list of drug review and consultation meeting in August 2015
Time of Update: 2020-04-03
From August 19 to 21, 2015, the drug review center organized the 7th drug review consultation meeting in Guangxi building, Beijing 101 experts were invited to attend the meeting At the same time, 13 a
-
The Academy of Military Sciences enlarged the recruitment for Ebola again, and the anti Ebola antibody entered the review status (review weekly report 53)
Time of Update: 2020-04-03
Introduction: 1 Beijing Kangchen Pharmaceutical Co., Ltd has entered the review stage of class 1 TiNi drugs; 2 After the recombinant Ebola virus vaccine, the Academy of Military Sciences has also decl
-
Clinical application of four McAb varieties completed by Hualan biology within one year
Time of Update: 2020-04-03
Xie Junmin, financial director and Secretary of Hualan biology, said in a conference call on the morning of August 26 that the company had submitted the clinical application of Herceptin mAb to the St
-
Strong cooperation - Hualan biology China joint laboratory was officially launched
Time of Update: 2020-04-03
On April 20, 2015, Hualan biology and sartorius China held the establishment and opening ceremony of "cell culture Joint Laboratory" in Hualan biomedical industrial park This ceremony was jointly atte
-
Summary of effective production approval documents in China (as of February 7, 2015)
Time of Update: 2020-04-03
As of February 7, 2015, the total number of domestic document numbers monitored by Xianda data 3.0 is 173594, belonging to 6725 enterprises respectively Among them, there are 168981 domestic approvals
-
Qianjiang pharmaceutical and TnI company of the United States launched the new drug application of "Zhongzhu 1018" in China
Time of Update: 2020-04-03
On the evening of March 10, Hubei Qianjiang Pharmaceutical Co., Ltd., a subsidiary of China Pearl holdings, signed a supplementary cooperation agreement with TnI Biotechnology Co., Ltd (TnI company fo
-
Top 100 new drug registration applications of national pharmaceutical enterprises in 2013
Time of Update: 2020-04-03
Note: 1 The ranking order is based on the total number of clinical application and production approval acceptance numbers in 2013; 2 Because the ranking is based on the total number of acceptance numb
-
April 2014 CDE drug review report
Time of Update: 2020-04-03
Recently, the drug registration applications accepted by CDE in April 2014 were analyzed in the insight pharmaceutical database of dingxiangyuan, with a total of 774 applications (calculated by accept
-
Hepatitis C treatment in China is facing severe challenges. New drugs may change the status quo
Time of Update: 2020-04-03
Recently, Roche and Geli Biotechnology (Hangzhou) Co., Ltd (hereinafter referred to as "Geli") jointly announced that they would cooperate in the R & D and production of new Roche hepatitis C drug da
-
The first clinical application of McAb in Wanle pharmaceutical, a subsidiary of Sinopharm
Time of Update: 2020-04-03
According to the information on July 18 on the website of CFDA, Shenzhen Wanle Pharmaceutical Co., Ltd., a subsidiary of CFDA, has accepted the application of class 2 therapeutic biological products f
-
Beijing food and drug administration organizes children's drug manufacturers to apply for national major new drug development projects
Time of Update: 2020-04-03
Recently, in order to promote the construction of the drug supply guarantee system for children in Beijing, SFDA, in close cooperation with the Municipal Commission of science and technology, organize
-
Approved clinical approval of kazinan 1.1 new drug CM082
Time of Update: 2020-04-03
The processing status of CM082 (cxhl1301192), a class 1.1 new drug of kananji Pharmaceutical Technology (Shanghai), was changed to "CFDA approval" on December 19, 2014, and clinical approval documents
-
Chongqing University and enterprise research and development of super bacterial vaccine obtained clinical approval; humanwell pharmaceutical indirectly participated in research and development enterprises
Time of Update: 2020-04-03
The recombinant Staphylococcus aureus vaccine, developed by the Third Military Medical University and Chongqing Yuanlun Biotechnology Co., Ltd jointly by the University and the enterprise, has been ap
-
"New Viagra" of Tianfang pharmaceutical needs at least 5 years to be listed
Time of Update: 2020-04-03
On July 10, a news that "tpn729ma, a new drug of Tianfang pharmaceutical industry absorbed and merged by China pharmaceutical, has been prepared and certified by the State Food and drug administration
-
It is expected that the production approval of levetiracetam, a class 3.1 antiepileptic drug of xinlitai, will be obtained this month
Time of Update: 2020-04-03
According to the information on the website of CFDA on June 9, the raw materials and tablets of 3.1 chemical drug levetiracetam declared by xinlitai for production have become "approved pending certif
-
The first phase clinical trial of a new class of Guizhou bailing chemical "tifentai"
Time of Update: 2020-04-03
On March 17, 2014, Guizhou bailing signed the technology development (entrustment) contract with Beijing bonoway Pharmaceutical Technology Development Co., Ltd the company is Party A and bonoway pharm
-
Three specifications of irbesartan hydrochlorothiazide tablets of Huahai Pharmaceutical Co., Ltd. have been approved by FDA for listing
Time of Update: 2020-04-03
In the evening of May 12, Huahai pharmaceutical announced that the company's three specifications of irbesartan hydrochlorothiazide tablets were approved by FDA for listing Irbesartan hydrochlorothiaz
-
Guizhou bailing: Notice on the progress of research and development project of new drug GZ50 of antitumor and chemotherapeutic drug 1.1
Time of Update: 2020-04-03
Securities code: 002424 securities abbreviation: Guizhou bailing Announcement No.: 2016-009 Guizhou bailing Enterprise Group Pharmaceutical Co., Ltd announcement on the progress of the research and de
-
X-Body announced the signing of multi million dollar development contract with Hengrui pharmaceutical
Time of Update: 2020-04-03
X-Body Biosciences today announced an exclusive agreement with Jiangsu Hengrui Pharmaceutical Co., Ltd (hereinafter referred to as "Hengrui"), a leading pharmaceutical company in China According to th
